ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies. The appointment of Susan as CBO is a significant milestone in ViroCell’s continuing operational development as a future leader in the clinical trial CDMO market and her appointment brings with it, Susan’s passion to assist clients in accelerating their innovative product candidates into and through clinical trials.